CollabRx is a leading company in cloud-based expert systems to inform healthcare decision-making. The company uses integration technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts.
The company announced today the release of its second generation Therapy Finder application for lung cancer. This specific application is a web-based decision support tool that enables oncologists to take into account the genetics of a patient’s tumor when determining a treatment plan. This second generation incorporates the results of recent advances in lung cancer clinical and translational research.
The app content is constantly kept up to date by CollabRx’s own scientists using the company’s proprietary semantic integration platform. This is a technology developed by CollabRx to enable the efficient and semi-automated gathering, annotation, and curation of the world’s knowledge on molecular medicine for oncology.
These apps are the first to be developed by CollabRx. The goal is to develop tools to help oncologists make informed decisions regarding their patients for all the common cancer types. For additional information about CollabRx and its Therapy Finder apps, which are freely available, please visit the company’s Web site at www.collabrx.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
